Advertisement

Use of recombinant human BMP-2 in orthopedic trauma

  • Michael Suk
Part of the Progress in Inflammation Research book series (PIR)

Abstract

It has been more than 40 years since Dr. Marshall Urist’s initial discovery of the osteoinductive activity of bone morphogenetic protein (BMP) [1, 2]. Today, as a direct result of that discovery, orthopedic surgeons have the ability to control osteogenesis through the local application of BMP in their patients. Osteoinduction is defined as the ability of a protein to mediate and induce bone formation in an extraossesous site. BMPs are the family of osteoinductive proteins that can be extracted from bone matrix and are responsible for embryonic skeletal formation, skeletal regeneration and bone healing. The first publications on the clinical use of extracts of human BMP from allograft bone matrix began in the late 1980s. This was followed in 1988 by the isolation of the DNA for individual BMP molecules from a purified extract and the subsequent recombinant production of different BMPs [3]. This recombinant production process is similar to the method used to manufacture human insulin and other protein-based drugs (such as erythropoietin and interferon); it enables the reproducible production of a single BMP, at a known concentration and at very high purity. The availability of recombinant human bone morphogenetic protein-2 (rhBMP-2, also known as dibotermin alfa) permitted the large-scale testing of different carriers and concentrations in preclinical animal models, prior to starting clinical studies and gaining regulatory approval of a synthetic rhBMP-2 product.

Keywords

Tibia Fracture Allograft Bone Orthopedic Trauma Recombinant Production Preclinical Animal Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Urist MR (1965) Bone: Formation by autoinduction. Science 150: 839–839CrossRefGoogle Scholar
  2. 2.
    Urist MR, Strates BS (1097) Bone morphogenetic protein. J Dent Res 50: 1392–1406Google Scholar
  3. 3.
    Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242: 1528–1534CrossRefGoogle Scholar
  4. 4.
    Reddi AH, Marshall R (2003) Urist: A renaissance scientist and orthopaedic surgeon. J Bone Joint Surg 85-A: 3–7Google Scholar
  5. 5.
    Urist MR, Granstein R, Nogami H, Svenson L, Murphy R (1977) Transmembrane bone morphogenesis across multiple-walled diffusion chambers. Arch Surg 122: 612–619Google Scholar
  6. 6.
    Johnson EE, Urist MR, Finerman GAM (1988) Bone morphogenetic protein augmentation grafting of resistant femoral nonunions: A preliminary report. Clin Orthop Relat Res 230: 257–265Google Scholar
  7. 7.
    Johnson EE, Urist MR, Finerman GA (1988) Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. Clin Orthop Relat Res 236: 249–257Google Scholar
  8. 8.
    Johnson EE, Urist MR, Finerman GAM (1990) Distal metaphyseal tibial nonunion: Deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop Relat Res 250: 234–240Google Scholar
  9. 9.
    Johnson EE, Urist MR, Finerman GAM (1992) Resistant nonunions and partial or complete segmental defects of long bones: Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop Relat Res 277: 229–237Google Scholar
  10. 10.
    Johnson EE, Urist MR (1998) One-stage lengthening of femoral nonunion augmented with human bone morphogenetic protein. Clin Orthop Relat Res 347: 105–116Google Scholar
  11. 11.
    Johnson EE, Urist MR (2000) Human bone morphogenetic protein allografting for reconstruction of femoral nonunion. Clin Orthop Relat Res 371: 61–74CrossRefGoogle Scholar
  12. 12.
    Zabka AG, Pluhar GE, Edwards RB 3rd, Manley PA, Hayashi K, Heiner JP, Kalscheur VL, Seeherman HJ, Markel HJ(2001) Histomorphometric description of allograft bone remodeling and union in a canine segmental femoral defect model: a comparison of rhBMP-2, cancellous bone graft, and absorbable collagen sponge. J Orthop Res 19: 318–327CrossRefGoogle Scholar
  13. 13.
    Sciadini MF, Johnson KD (2000) Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res 18: 289–302CrossRefGoogle Scholar
  14. 14.
    Hollinger JO, Schmitt JM, Buck DC, Shannon R, Joh SP, Zegzula HD, Wozney J (1998) Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration. J Biomed Mater Res 43: 356–364CrossRefGoogle Scholar
  15. 15.
    Li RH, Wozney JM (2001) Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol 19: 255–265CrossRefGoogle Scholar
  16. 16.
    Cook SD, Patron LP, Brown S (2005) Evaluation of INFUSE bone graft in a canine critical size defect: effect of sponge placement on healing. Transactions of the Orthopaedic Trauma Association Annual Meeting, October 20-22, 2005, Ottawa, Ontario, Canada, 18: Paper no. 36Google Scholar
  17. 17.
    Jones C, Badura J, Marotta J (2007) Examination of extending rhBMP-2/absorbable collagen sponge (ACS) with allograft and ceramic in a canine critical-sized segmental defect. Transactions of the Orthopaedic Research Society Annual Meeting, February 11–14, 2007, San Diego, California, USA, 53: Poster no. 354Google Scholar
  18. 18.
    Bouxsein ML, Turek TJ, Blake CA, D’Augusta D, Li X, Stevens M, Seeherman HJ, Wozney JM (2001) Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 83-A: 1219–1230Google Scholar
  19. 19.
    Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM, Li XJ (1998) Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 13: 1483–1490CrossRefGoogle Scholar
  20. 20.
    Gustilo RB, Mendoza RM, Williams DN (1984) Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma 24: 742–746CrossRefGoogle Scholar
  21. 21.
    Gustilo RB, Anderson JT (1976) Prevention of infection in the treatment of one thousand and twenty-five open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am 58: 453–458Google Scholar
  22. 22.
    Bosse MJ, MacKenzie EJ, Kellam JF, Burgess AR, Webb LX, Swiontkowski MF, Sanders RW, Jones AL, McAndrew MP, Patterson BM, McCarthy ML, Travison TG, Castillo RC (2002) An analysis of outcomes of reconstruction or amputation of leg-threatening injuries. N Engl J Med 347: 1924–1931CrossRefGoogle Scholar
  23. 23.
    Riedel GE, Valentin-Opran A (1999) Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report. Orthopedics 22: 663–665Google Scholar
  24. 24.
    Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG et al (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A: 2123–2134Google Scholar
  25. 25.
    Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A (2006) Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88: 1258–1265CrossRefGoogle Scholar
  26. 26.
    Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88: 1431–1441CrossRefGoogle Scholar
  27. 27.
    Kuklo TR, Groth AT, Andersen RC, Islinger RB (2005) Use of rhBMP-2 for open segmental tibia fractures in Iraq. Transactions from the Orthopaedic Trauma Association Annual Meeting, Ottawa, Ontario, 20-22 October 2005, Paper no: 49Google Scholar
  28. 28.
    Schwartz ND, Hicks BM (2006) Segmental bone defects treated using recombinant human bone morphogenetic protein. J Orthopaedics 3(2) e2, accessed on May 15, 2007 at http://www.jortho.org/2006/3/2/e2/index.htm Google Scholar
  29. 29.
    Hicks MB (2006) BMP-2 and its use in nonunion and malunions Transactions from the Orthopaedic Trauma Association annual meeting, Phoenix, AZ, 5-7 October 2006, Poster no: 27Google Scholar
  30. 30.
    Cole JD, Nguyen S, Lamb DL (2006) Review of healing with rhBMP-2/ACS in the medicareaged population. Transactions from the Orthopaedic Trauma Association annual meeting, Phoenix, AZ, 5-7 October 2006, Poster no: 102Google Scholar
  31. 31.
    Ringler JR, Endres TJ, Jones CB (2007) Clinical outcomes for long-bone nonunions implanted with bone morphogenetic protein. Transactions from the American Academy of Orthopaedic Surgeons annual meeting, San Diego, CA, 14-18 February 2007, Poster no: 508Google Scholar
  32. 32.
    Obremskey Wt, Kregor PJ, Shuler FD, Tressler MA (2006) Bone morphogenic proteins compared to iliac crest bone graft in long bone nonunions. Transactions from the Orthopaedic Trauma Association annual meeting, Phoenix, AZ, 5-7 October 2006, Paper no: 15Google Scholar
  33. 33.
    Richards BS, Johnston CE, Welch RD, Shrader MW (2006) Use of rhBMP-2 in congenital pseudarthorsis of the tibia. Transactions from the American Academy of Orthopaedic Surgeons annual meeting, Chicago, IL, 22-26 March 2006, Poster no: P252Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Michael Suk
    • 1
  1. 1.University of Florida — Shands JacksonvilleJacksonvilleUSA

Personalised recommendations